^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    GCR antagonist

    Related drugs:
    7d
    Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer (clinicaltrials.gov)
    P1, N=42, Completed, University of Chicago | Active, not recruiting --> Completed
    Trial completion
    |
    Xtandi (enzalutamide) • Lifyorli (relacorilant)
    1m
    Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer (clinicaltrials.gov)
    P1, N=35, Active, not recruiting, University of Chicago | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    Xtandi (enzalutamide) • Lifyorli (relacorilant)
    1m
    DAZALS: Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov)
    P2, N=279, Recruiting, Corcept Therapeutics | Active, not recruiting --> Recruiting
    Enrollment open
    |
    SOD1 (Superoxide Dismutase 1)
    2ms
    Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome (clinicaltrials.gov)
    P2, N=125, Active, not recruiting, Corcept Therapeutics | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Lifyorli (relacorilant)
    2ms
    Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=60, Recruiting, Corcept Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • albumin-bound paclitaxel • Lifyorli (relacorilant)
    2ms
    Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study) (clinicaltrials.gov)
    P2, N=40, Recruiting, VA Office of Research and Development | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026 | N=88 --> 40
    Enrollment change • Trial completion date • Trial primary completion date
    2ms
    Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Corcept Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab)
    4ms
    DAZALS: Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov)
    P2, N=279, Active, not recruiting, Corcept Therapeutics | Trial completion date: May 2027 --> Nov 2027 | Trial primary completion date: Oct 2024 --> Sep 2026
    Trial completion date • Trial primary completion date
    4ms
    Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Corcept Therapeutics
    New P1/2 trial
    |
    Opdivo (nivolumab)
    4ms
    Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Corcept Therapeutics
    New P2 trial
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • albumin-bound paclitaxel • Lifyorli (relacorilant)
    6ms
    BELLA: Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (clinicaltrials.gov)
    P2, N=270, Recruiting, Corcept Therapeutics | N=90 --> 270
    Enrollment change
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • Lifyorli (relacorilant)
    6ms
    Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, AVM Biotechnology Inc | Trial completion date: Mar 2025 --> Mar 2032 | Trial primary completion date: Dec 2024 --> Dec 2031
    Trial completion date • Trial primary completion date
    |
    dexamethasone sodium phosphate (AVM0703)